会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • スピロ化合物
    • SPIRO化合物
    • WO2003014083A1
    • 2003-02-20
    • PCT/JP2002/007922
    • 2002-08-02
    • 萬有製薬株式会社深見 竹広野々下 克昌相良 武岸野 博之
    • 深見 竹広野々下 克昌相良 武岸野 博之
    • C07D209/96
    • C07D401/12A61K31/4747C07D209/96C07D307/94C07D403/12C07D405/12C07D471/10C07D491/10
    • The invention relates to compounds represented by the general formula (‖) or the like: (‖) [wherein A is a linear C 1−6 hydrocarbon group which may be substituted or interrupted by oxygen or nitrogen; Ar 1 is an aryl or heteroaryl group which may be substituted; n is 0 or 1; R 0 is hydrogen or lower alkylene attached to an arbitrary binding site of A; T, U, V and W are each optionally substituted methine or nitrogen, with the proviso that at least two of them are each methine; X is −N(SO 2 R 1 )−, −N(COR 2 )−, or −CO−; Y is −C(R 3 )(R 4 )−, −O−, or −N(R 5 )−; and Z is methine or nitrogen]. The compounds exhibit NPY antagonism and are therefore useful as treating agents for various diseases in which NPY participates, e.g., circulatory diseases, central nervous system diseases such as hyperphagia, metabolic diseases such as obesity and diabetes, and so on.
    • 本发明涉及由通式(‖)等表示的化合物:(‖)[其中A是可以被氧或氮取代或中断的直链C 16-18烃基; Ar 1是可以被取代的芳基或杂芳基; n为0或1; R 0是氢或连接到A的任意结合位点的低级亚烷基; T,U,V和W各自是任选取代的次甲基或氮,条件是它们中的至少两个都是次甲基; X是-N(SO 2)n - , - (COR 2) - 或-CO-; Y是-C(R 3)3, - 或-O-(R 5)。 Z是次甲基或氮]。 化合物表现出NPY拮抗作用,因此可用作NPY参与的各种疾病的治疗剂,例如循环系统疾病,中枢神经系统疾病如食欲过盛,代谢疾病如肥胖症和糖尿病等。